519 related articles for article (PubMed ID: 34741682)
1. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
Zinzani PL; Minotti G
J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
[TBL] [Abstract][Full Text] [Related]
2. Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma.
Xu B
Eur J Clin Pharmacol; 2022 May; 78(5):707-719. PubMed ID: 35061047
[TBL] [Abstract][Full Text] [Related]
3. Newly approved anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Davis JA; Shockley A; Glode AE
J Oncol Pharm Pract; 2022 Apr; 28(3):686-690. PubMed ID: 35037773
[No Abstract] [Full Text] [Related]
4. Loncastuximab tesirine for treatment of relapsed or refractory diffuse large B cell lymphoma.
Goparaju K; Caimi PF
Expert Opin Biol Ther; 2021 Nov; 21(11):1373-1381. PubMed ID: 34505550
[TBL] [Abstract][Full Text] [Related]
5. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF; Ai W; Alderuccio JP; Ardeshna KM; Hamadani M; Hess B; Kahl BS; Radford J; Solh M; Stathis A; Zinzani PL; Havenith K; Feingold J; He S; Qin Y; Ungar D; Zhang X; Carlo-Stella C
Lancet Oncol; 2021 Jun; 22(6):790-800. PubMed ID: 33989558
[TBL] [Abstract][Full Text] [Related]
6. Evaluating efficacy and safety of loncastuximab tesirine injection for the treatment of adult patients with relapsed or refractory large B-cell lymphoma.
Ahmed N; Hamadani M
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1313-1320. PubMed ID: 34597242
[TBL] [Abstract][Full Text] [Related]
7. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G; Duell J; González Barca E; Tournilhac O; Jurczak W; Liberati AM; Nagy Z; Obr A; Gaidano G; André M; Kalakonda N; Dreyling M; Weirather J; Dirnberger-Hertweck M; Ambarkhane S; Fingerle-Rowson G; Maddocks K
Lancet Oncol; 2020 Jul; 21(7):978-988. PubMed ID: 32511983
[TBL] [Abstract][Full Text] [Related]
8. A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma.
Kahl BS; Hamadani M; Radford J; Carlo-Stella C; Caimi P; Reid E; Feingold JM; Ardeshna KM; Solh M; Heffner LT; Ungar D; He S; Boni J; Havenith K; O'Connor OA
Clin Cancer Res; 2019 Dec; 25(23):6986-6994. PubMed ID: 31685491
[TBL] [Abstract][Full Text] [Related]
9. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
10. Loncastuximab Tesirine: First Approval.
Lee A
Drugs; 2021 Jul; 81(10):1229-1233. PubMed ID: 34143407
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
[TBL] [Abstract][Full Text] [Related]
12. Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation.
Sermer D; Elavalakanar P; Abramson JS; Palomba ML; Salles G; Arnason J
Blood Rev; 2023 Jan; 57():101002. PubMed ID: 35989138
[TBL] [Abstract][Full Text] [Related]
13. Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Salles G; Długosz-Danecka M; Ghesquières H; Jurczak W
Expert Opin Biol Ther; 2021 Apr; 21(4):455-463. PubMed ID: 33554668
[TBL] [Abstract][Full Text] [Related]
14. Loncastuximab tesirine for diffuse large B-cell lymphoma.
Zurko J; Hamadani M
Drugs Today (Barc); 2021 Dec; 57(12):733-743. PubMed ID: 34909802
[TBL] [Abstract][Full Text] [Related]
15. Safety of loncastuximab tesirine-lpyl in diffuse large B-cell lymphoma with severe hepatic dysfunction.
Baek GT; Huang IJ; Gopal AK
Cancer; 2023 Aug; 129(15):2279-2283. PubMed ID: 37208793
[TBL] [Abstract][Full Text] [Related]
16. Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma.
Lu Q; Huang H; Tang S; Wang Y; Yang DH
Drugs Today (Barc); 2021 Sep; 57(9):571-580. PubMed ID: 34586105
[TBL] [Abstract][Full Text] [Related]
17. Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma.
Pirosa MC; Stathis A; Zucca E
Hum Vaccin Immunother; 2024 Dec; 20(1):2309701. PubMed ID: 38299612
[TBL] [Abstract][Full Text] [Related]
18. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.
Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E
Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140
[TBL] [Abstract][Full Text] [Related]
19. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
20. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M; Radford J; Carlo-Stella C; Caimi PF; Reid E; O'Connor OA; Feingold JM; Ardeshna KM; Townsend W; Solh M; Heffner LT; Ungar D; Wang L; Boni J; Havenith K; Qin Y; Kahl BS
Blood; 2021 May; 137(19):2634-2645. PubMed ID: 33211842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]